Predicting Risk of Emerging Drugs with In silico and Clinical Toxicology
 
WHAT IS PREDICT
 
New psychoactive substances (NPS) are also referred to as research chemicals, designer drugs or legal highs. Over the past years, the availability of NPS has shown an exponential increase. Current risk assessments of NPS are frequently based on individual case studies without any information on exposure or dose.  
HEALTH RISKS
 
Our product is designed to predict individual health risks from systematic, controlled NPS trials in humans and animals.
 
 
DATA BASE
 
Our product will build a reference data base from controlled studies in humans that will contain information on metabolomics, neurocognitive function, subjective experience and vital signs under the influence of scheduled drugs and NPS. In addition, patterns of drug use and perceived risk of NPS will be studied via web surveys.
PROFILING
 
Our product will also determine metabolomic profiles of a large range of NPS in rodents and compare and validate those against metabolomic profiles in humans.
 
 
As a final step, all human reference data on drug associated individual risk and animal metabolomics will be integrated in an in silico model.

WHO IS INVOLVED

 
MAASTRICHT UNIVERSITY
DR. KIM KUYPERS
investigator / supervisor
senior expert
DR. EEF THEUNISSEN
investigator / supervisor
senior expert
PROF. DR. JAN RAMAEKERS
coordinator
PHARM.D. WIM BEST
key-expert
CORRY VAN GURP
financial controller
ELIZA DE SOUSA
FERNANDES PERNA
researcher
project manager
TRIMBOS INSTITUTE
DR. TIBOR BRUNT
principal investigator
senior expert
DR. MARGRIET VAN LAAR
senior expert
DR. ANNABEL VREEKER
project manager
HOSPITAL DEL MAR
MEDICAL RESEARCH INSTITUTE
DR. OSCAR POZO
investigator
expert
PROF. DR. MAGI FARRE
co-principle investigator
senior expert
PROF. DR. RAFAEL DE LA TORRE
principle investigator
senior expert
DR. EULALIA OLESTI MUNOZ
PROUS INSTITUTE
FOR BIOMEDICAL RESEARCH
DR. MARCEL.LI CARBO
principle investigator
senior expert
DR. ANTONI VALENCIA
computational modeller
senior expert
DR. JOSEP PROUS JR.
investigator
expert
PROF. DR. STEFAN TOENNES
 
THE PREDICT PROJECT IN 4 STEPS
1.
Websurveys to rapidly collect data about subjective effects and perceived risks of current NPS in The Netherlands, Sweden and Spain
 
 
 
2.
Controlled studies in humans to assess neurocognitive, subjective, physiological effects as well as metabolomics (i.e. determination of chemical drug/metabolite fingerprints in urine) of probe NPS and control drugs.
 
3.
Toxicometabolomic studies in rodents. Metabolomic profiles of 25 NPS in animal models will be evaluated and qualified relative to  the metabolomics in NPS and control substances obtained in human studies.
 
4.
Develop a novel testing system to determine toxicity of NPS, based on animal and human data collected in steps 1-3. This novel testing system will be an in silico model: a high-throuput in vitro model, based on computer simulation. It predicts individual health risk of future NPS from a metabolomic sample in urine.
 
WHO WILL BENEFIT
 
Specific target groups include:
 
EMCDDA
EU Early Warning System
UNODC
WHO
(Potential) drug users
Institutes for drug research
Universities
Academics
Policy makers
NGO’s and prevention professionals
Health and Law government
 
I'm a title.
WHAT IS OUR PRODUCT
 
The primary goal of this project is to gain more scientific insight into the (toxic) effects of NPS to aid future EU risk assessments and inform the general public. The main results will be the development of validated and fast screening tools to establish risks of future NPS and speed up European risk assessment. These tools include a standardized online survey to rapidly assess adverse effects of NPS and a metabolomic / in silico model to predict individual health risks of NPS.
 

Sign up for more information!

 

PREDICT is co-funded by the European Union.

 

Designed by Onlime